Avo In R/R And Previously Untreated MCL

NCT04855695 PHASE1, PHASE2 RECRUITING

This research study is evaluating the combination of three drugs - acalabrutinib, venetoclax, and obinutuzumab - as a possible treatment for relapsed or refractory and untreated mantle cell lymphoma (MCL). The names of the study drugs involved in this study are: * Acalabrutinib * Venetoclax * Obinutuzumab

Details

Lead sponsor	Austin I Kim
Phase	PHASE1, PHASE2
Status	RECRUITING
Enrolment	72
Start date	Fri Jul 02 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Fri Dec 31 2027 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Mantle Cell Lymphoma
• Refractory Lymphoma

Interventions

• Acalabrutinib
• Venetoclax
• Obinutuzumab

Countries

United States